The filing positions one of 2017’s star performers on European exchanges to start trading in the U.S. and fund a phase 3 pancreatic cancer trial.

Allena arrives on Wall Street armed with data from two phase 2 flops and a pivotal trial design that has so far failed to win over the FDA.

PanOptica plans to start trialling the small molecule anti-vascular endothelial growth factor eye drop early next year.

The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt.

A report from CNBC says that PayPal founder Peter Thiel and Facebook investor Sean Parker are investing in a new, secretive oncology biotech company.

Massachusetts startup Palleon Pharmaceuticals has raised $47.6 million to fund the development of cancer drugs that target sugar-sensing molecules.

Immatics turned to existing investors and new partner Amgen to put together the round, which brings its total raised to date up toward €200 million.

Ablynx is gearing up to commercialize the anti-von Willebrand factor single-domain antibody in the U.S. and Europe.

The idea is to manage the risks inherent in R&D by placing bets on eight to 10 early-stage assets and selling those that show promise in the clinic. 

Vivek Ramaswamy’s Roivant has just put another sizable block of cash behind a hepatitis B program in development at Canada’s Arbutus Biopharma.

Venture Capital